MYD88 (L265P) Mutation

MYD88 (L265P) mutation has garnered a lot of excitement because of its usefulness in diagnosing lymphoplasmacytic lymphoma (LPL).  Traditionally, LPL has been difficult to diagnose because exclusion of other B-cell neoplasms with plasmacytic differentiation is required. MYD88 mutations are present in approximately 90% of cases of LPL, and in a much lower percentage of cases of B cell lymphomas, which are typically in the differential diagnosis of LPL.
 MYD88 mutation frequency

References
Harmon CM, Smith LB. B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation. Surg Pathol Clin. 2016;9: 11–28. doi:10.1016/j.path.2015.09.007
 
WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues.  SH Swerdlow, et al. International Agency for Research on Cancer. Lyon, 2008. p. 194-195
 
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127: 2375–2390. doi:10.1182/blood-2016-01-643569
 
Martinez-Lopez A, Curiel-Olmo S, Mollejo M, Cereceda L, Martinez N, Montes-Moreno S, et al. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma. Am J Surg Pathol. 2015;39: 644–651. doi:10.1097/PAS.0000000000000411
 
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367: 826–833. doi:10.1056/NEJMoa1200710